

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2020**

Reference is made to the annual report of Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”, and its subsidiaries, the “**Group**”) for the year ended 31 December 2020 published on 29 April 2021 (the “**Annual Report**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the Annual Report.

The board of directors (the “**Board of Directors**”) of the Company would like to provide further details on research and development expenses of RMB1,778 million recorded by the Group for the year ended 31 December 2020. The breakdown of research and development expenses of the Group during the year is set out below:

Research and Development Expenses

	Year ended 31 December	
	2020	2019
	RMB'000	RMB'000
Clinical research and technical service expenses	1,441,082	743,388
Staff salary and welfare	243,119	144,684
Share-based payment expenses	10,740	6,124
Depreciation and amortization	44,468	17,728
Others	38,614	34,176
Total	<u>1,778,023</u>	<u>946,100</u>

The above additional information does not affect other information contained in the Annual Report and, save as disclosed in this announcement, the remaining contents of the Annual Report remain unchanged.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 2 November 2021

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.

* *For identification purpose only*